Jabez Biosciences

Executive Summary

Jabez Biosciences is a San Diego-based private biotech company founded in 2018, focusing on small-molecule cancer therapeutics. The company’s '3-S' model aims to develop drugs that are well-tolerated, affordable to produce, and seamlessly integrate with existing treatment regimens to improve patient outcomes. By prioritizing safety, cost-effectiveness, and combinability, Jabez seeks to address key limitations in current oncology therapies. The company is currently in Phase 1 clinical development, indicating its lead candidate has advanced from preclinical studies into early human trials. While specific details about the lead program are limited, the strategic emphasis on tolerability and affordability suggests a differentiated positioning in the competitive oncology landscape. The company is privately held and has not disclosed total funding or valuation, but its progress to Phase 1 implies prior successful financing and regulatory clearance.

Upcoming Catalysts (preview)

• TBDInitiation of Phase 1 clinical trial for lead candidate40% success